Shareholder update to review AVA6000 Phase 1a data

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, will hold an online shareholder event via the Investor Meet Company (“IMC”) platform on Wednesday 13 December at 11:00 a.m. GMT.

Avacta’s Chief Executive Officer, Alastair Smith, Chief Scientific Officer, Fiona McLaughlin and Consultant Chris Coughlin will present a detailed review of the AVA6000 clinical trial’s Phase 1a data, followed by an investor Q&A. Questions can be submitted in advance via the IMC platform.

Investors who already follow Avacta on IMC will automatically be invited to join the live stream. Investors who do not have an IMC account can sign up for free at and then click “Add to meet” on the Avacta page in order to receive an invitation.